AN2 Thereapeutics Inc.
13F holders, Q1 2026 (March 31)1holders
0new positions
0sold out
$3.42avg. 13F price*
At the end of Q1 2026, 1 institutions reported holding AN2 Thereapeutics Inc. in their 13F filings, unchanged from Q4 2025. 0 opened new positions and 0 sold out. The largest holder was Aldebaran Capital, LLC ($1.3M).
- Company
- AN2 Thereapeutics Inc.
- CUSIP
- 373261056
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q4 2025 → Q1 2026: 5,000 shares sold, net −5,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Aldebaran Capital, LLC | 0.97% | Reduce -1.3% | 371,770 | $1.3M |
"% of holder's portfolio" is AN2 THEREAPEUTICS INC's weight in each manager's 13F, not the share of AN2 Thereapeutics Inc. the manager owns.